Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
First patient recruited to presutineb trial

The PReSUTINeB trial will investigate if Uro Vaxom can reduce the incidence of symptomatic UTIs in 48 participants in two centres in the UK (Stoke Mandeville Hospital, Buckinghamshire and Oxford Centre for Enablement). The trial has now recruited its first patient at the Oxford Centre for Enablement. The investigators will also look at the signs and symptoms a participant experiences during a symptomatic UTI.